Exane Derivatives Eli Lilly & CO Transaction History

Exane Derivatives

$157 Million
Q2 2022

A detailed history of Exane Derivatives transactions in Eli Lilly & CO stock. As of the latest transaction made, Exane Derivatives holds 790 shares of LLY stock, worth $582,759. This represents 0.16% of its overall portfolio holdings.

Number of Shares

790

Previous 2,481 68.16%

Holding current value

$582,759

Previous $710,000 63.94%

% of portfolio

0.16%

Previous 0.22%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$278.73 - $327.27 $471,332 - $553,413	-1,691 Reduced 68.16%	790 $256,000
Q1 2022 Apr 22, 2022	BUY	$234.69 - $291.66 $161,466 - $200,662	688 Added 38.37%	2,481 $710,000
Q4 2021 Jan 28, 2022	BUY	$224.85 - $279.04 $9,668 - $11,998	43 Added 2.46%	1,793 $495,000
Q3 2021 Oct 26, 2021	BUY	$221.6 - $272.71 $55,843 - $68,722	252 Added 16.82%	1,750 $404,000
Q2 2021 Jul 28, 2021	BUY	$180.55 - $233.54 $18,235 - $23,587	101 Added 7.23%	1,498 $343,000
Q1 2021 Apr 30, 2021	SELL	$164.32 - $212.72 $435,940 - $564,346	-2,653 Reduced 65.51%	1,397 $260,000
Q4 2020 Jan 27, 2021	BUY	$130.46 - $172.63 $382,508 - $506,151	2,932 Added 262.25%	4,050 $683,000
Q3 2020 Oct 06, 2020	SELL	$146.22 - $169.13 $394,062 - $455,805	-2,695 Reduced 70.68%	1,118 $165,000
Q2 2020 Jul 10, 2020	SELL	$136.42 - $164.18 $211,450 - $254,479	-1,550 Reduced 28.9%	3,813 $626,000
Q1 2020 Apr 17, 2020	SELL	$119.05 - $147.35 $48,929 - $60,560	-411 Reduced 7.12%	5,363 $743,000
Q4 2019 Jan 22, 2020	SELL	$106.92 - $132.43 $81,579 - $101,044	-763 Reduced 11.67%	5,774 $758,000
Q3 2019 Oct 15, 2019	BUY	$106.79 - $116.16 $592,577 - $644,571	5,549 Added 561.64%	6,537 $731,000
Q2 2019 Jul 12, 2019	BUY	$110.79 - $129.32 $7,755 - $9,052	70 Added 7.63%	988 $0
Q1 2019 Apr 24, 2019	SELL	$111.31 - $131.02 $970,289 - $1.14 Million	-8,717 Reduced 90.47%	918 $0
Q4 2018 Jan 31, 2019	SELL	$105.9 - $118.64 $246,641 - $276,312	-2,329 Reduced 19.47%	9,635 $1.11 Million
Q3 2018 Oct 24, 2018	SELL	$85.86 - $107.31 $271,832 - $339,743	-3,166 Reduced 20.93%	11,964 $0
Q2 2018 Jul 19, 2018	SELL	$75.7 - $86.88 $92,883 - $106,601	-1,227 Reduced 7.5%	15,130 $0
Q1 2018 Apr 30, 2018	SELL	$74.21 - $87.6 $172,909 - $204,108	-2,330 Reduced 12.47%	16,357 $0
Q4 2017 Jan 29, 2018	BUY	$81.94 - $87.89 $1.48 Million - $1.59 Million	18,051 Added 2838.21%	18,687 $0
Q3 2017 Oct 18, 2017	BUY	$77.07 - $85.54 $49,016 - $54,403	636	636 $0

Others Institutions Holding LLY

# of Institutions

4,388

Shares Held

821M

Call Options Held

10M

Put Options Held

10.8M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $701B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Account

Exane Derivatives Eli Lilly & CO Transaction History